Advertise with us
Clinical Group

Archives of Clinical Nephrology

ISSN: 2581-3870

DOI

CC By

Abstract Open Access
Editorial PTZAID: ACN-1-104

Use of Iron Therapy in Chronic Kidney Disease

Jacques Rottembourg* and Guy Rostoker

Anemia is a common complication in patients with chronic kidney disease (CKD), and increases with the progression of renal dysfunction [1]. The main cause of anemia is the inadequate production of erythropoietin (EPO), a glycoprotein mainly produced by the kidney responsible for the growth of erythroid cells in the bone marrow [2]. Iron deficiency is another common cause of anemia in these patients and is a major cause of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) [3]. Approximately, 50% of patients with CKD, who have anemia and are not receiving ESA or iron supplementation show depleted iron stores in their bone marrow [4]. Although the use of intravenous iron in hemodialysis patients has significantly increased during the last decade [5], the appropriate iron dosing strategy in CKD remains debatable.

Published on: Jan 6, 2016 Pages: 1-3

Full Text PDF Full Text HTML DOI: 10.17352/acn.000004

Advertisements

Peertechz @Social

Peertechz Tweets

Case Reports

Pinterest on ACN